Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Receives Consensus Recommendation of “Hold” from Brokerages

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.75.

A number of analysts have recently issued reports on ADIL shares. Brookline Capital Markets downgraded shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday. Needham & Company LLC downgraded shares of Adial Pharmaceuticals to a “buy” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Monday, April 20th.

Adial Pharmaceuticals Stock Performance

Adial Pharmaceuticals stock opened at $2.98 on Monday. The stock has a market cap of $6.38 million, a P/E ratio of -0.37 and a beta of 1.46. Adial Pharmaceuticals has a fifty-two week low of $1.31 and a fifty-two week high of $18.90. The firm’s fifty day moving average price is $1.86 and its 200-day moving average price is $3.60.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings results on Friday, May 8th. The company reported ($1.48) earnings per share for the quarter, topping the consensus estimate of ($2.73) by $1.25. Sell-side analysts predict that Adial Pharmaceuticals will post -7.09 earnings per share for the current year.

Institutional Trading of Adial Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ADIL. Citadel Advisors LLC bought a new stake in Adial Pharmaceuticals in the third quarter worth $51,000. Jane Street Group LLC lifted its stake in Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after purchasing an additional 109,500 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Adial Pharmaceuticals in the fourth quarter worth $562,000. 16.41% of the stock is owned by institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.